Literature DB >> 28292253

The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders.

Kai Y Mak1, Indu G Rajapaksha1, Peter W Angus2, Chandana B Herath1.   

Abstract

INTRODUCTION: The first human adeno-associated virus (AAV) was originally discovered in 1960s as a contaminant of adenovirus stock preparation and thus it had not been of medical interest. Throughout the last three decades AAV has gained popularity to be used in gene therapy, mainly due to its replicative defectiveness and lack of pathogenicity in human. In addition, its ability to mediate stable and long-term expression in both non-dividing and dividing cells with specific tissue tropism makes AAV one of the most promising candidates for therapeutic gene transfer to treat many inherited as well as non-inherited disorders. Moreover, the use of AAV is not only restricted to overexpression of recombinant transgene, but also to over-express short hairpin RNA and microRNA to knockdown the expression of genes in targeted tissues. DISCUSSION AND
CONCLUSION: This review is organized into four parts. In the first part of the review, we discuss about the discovery and history of AAV, followed by detailed AAV biology such as virus genome, virus structure and its life cycle. In the second part of the review, the discussion is centred on the molecular mechanisms of AAV and tissue transduction, including receptor recognition and cell binding, endosomal entry, virus uncoating, nuclear entry and genome replication. Advantages and limitations of using AAV as a safe vehicle for gene delivery is also discussed. In the third part of the review, we discuss about the most commonly used AAV serotypes and variants isolated from human and non-human primates, focusing on their diverse tissue tropisms, transduction efficiency, immunological profiles and their applications in animal studies. Final part of the review focuses on the recent progress of in-vivo gene transfer using AAV for inherited and non-inherited diseases in both preclinical and clinical settings with a special emphasis on potential clinical applications of AAV in the field of liver disease. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Adeno-associated virus; angiotensin converting enzyme 2; gene therapy; liver; non-inherited disorders; renin angiotensinzzm321990system; viral vector

Mesh:

Year:  2017        PMID: 28292253     DOI: 10.2174/1566523217666170314141931

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  9 in total

1.  Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity.

Authors:  Laurent Bartolo; Stéphanie Li Chung Tong; Pascal Chappert; Dominique Urbain; Fanny Collaud; Pasqualina Colella; Isabelle Richard; Giuseppe Ronzitti; Jocelyne Demengeot; David A Gross; Federico Mingozzi; Jean Davoust
Journal:  JCI Insight       Date:  2019-06-06

Review 2.  Complexity of immune responses to AAV transgene products - Example of factor IX.

Authors:  Roland W Herzog
Journal:  Cell Immunol       Date:  2017-05-29       Impact factor: 4.868

3.  An in Vivo miRNA Delivery System for Restoring Infarcted Myocardium.

Authors:  Huaxiao Yang; Xulei Qin; Huiyuan Wang; Xin Zhao; Yonggang Liu; Hung-Ta Wo; Chun Liu; Masataka Nishiga; Haodong Chen; Jing Ge; Nazish Sayed; Oscar J Abilez; Dan Ding; Sarah C Heilshorn; Kai Li
Journal:  ACS Nano       Date:  2019-06-07       Impact factor: 15.881

4.  Human Metaplastic Breast Carcinoma and Decorin.

Authors:  Pia Boström; Annele Sainio; Natalja Eigėlienė; Anne Jokilammi; Klaus Elenius; Ilkka Koskivuo; Hannu Järveläinen
Journal:  Cancer Microenviron       Date:  2017-06-26

Review 5.  Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.

Authors:  Céline Vandamme; Oumeya Adjali; Federico Mingozzi
Journal:  Hum Gene Ther       Date:  2017-11       Impact factor: 5.695

6.  Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.

Authors:  Fengqin Zhu; Yibo Wang; Zhen Xu; Haiyang Qu; Hairong Zhang; Lingling Niu; Honglu Xue; Dehuai Jing; Heng He
Journal:  Mol Med Rep       Date:  2018-12-11       Impact factor: 2.952

7.  Angiotensin Converting Enzyme-2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver.

Authors:  Indu G Rajapaksha; Lakmie S Gunarathne; Khashayar Asadi; Ross Laybutt; Sof Andrikopoulous; Ian E Alexander; Mathew J Watt; Peter W Angus; Chandana B Herath
Journal:  Hepatol Commun       Date:  2021-12-23

8.  Angiotensin 1-7 Overexpression Mediated by a Capsid-optimized AAV8 Vector Leads to Significant Growth Inhibition of Hepatocellular Carcinoma In vivo.

Authors:  Yingying Mao; Nana Pei; Xinglu Chen; Huiying Chen; Renhe Yan; Na Bai; Andrew Li; Jinlong Li; Yanling Zhang; Hongyan Du; Baihong Chen; Colin Sumners; Xuejun Wang; Shengqi Wang; Hongwei Li
Journal:  Int J Biol Sci       Date:  2018-01-11       Impact factor: 6.580

9.  Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65.

Authors:  Eloise Hudry; Eva Andres-Mateos; Eli P Lerner; Adrienn Volak; Olivia Cohen; Bradley T Hyman; Casey A Maguire; Luk H Vandenberghe
Journal:  Mol Ther Methods Clin Dev       Date:  2018-07-23       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.